Axsome Therapeutics Q3 2024 Earnings Report

Axsome Therapeutics EPS Results

• Actual EPS: -$1.34
• Consensus EPS: -$1.38
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: -$1.32

Axsome Therapeutics Revenue Results

• Actual Revenue: $104.76 million
• Expected Revenue: $98.71 million
• Beat/Miss: Beat by +$6.05 million
• YoY Revenue Growth: N/A

Axsome Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: Before Market Opens

Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.